| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.097 | 0.1 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.1 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.086 | 0.1 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |